3 hours Bristol-Myers Squibb’s Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout Investor's Business Daily
Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday.
The post Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout appeared firs…
Bristol · Bristol-Myers Squibb (BMY)